Cantor Fitzgerald came away from last week’s conference with reinforced conviction on Gossamer Bio (GOSS), telling investors in a research note that sentiment is clearly improving ahead of the February 2026 PROSERA readout. The firm, which has an Overweight rating on Gossamer Bio shares, says the market is still mis-pricing seralutinib’s odds, even with the recent stock run-up.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio upgraded to Buy from Neutral at UBS
- Gossamer Bio’s Seralutinib: Promising Long-Term Therapy with Upcoming Catalysts
- Gossamer Bio Reports Q2 2025 Financial Results
- Gossamer Bio’s Promising Clinical Advancements and Strategic Positioning Earns Buy Rating
- Gossamer Bio reports Q2 EPS (17c) , consensus (18c)